文献速递肿瘤 PET/CT

18F-PSMA-1007 PET/CT 识别非转移性高危前列腺癌的价值

The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer.
PubMed 文献 · EJNMMI Res · 2020-11-10

回顾性分析101例原发性非转移性前列腺癌患者,按EAU指南分为中危组和高危组,测量原发灶SUVmax。结果显示高危组SUVmax显著高于中危组(中位16.85 vs 7.80,P<0.001),SUVmax与PSA水平及Gleason评分正相关,以9.05为界值识别高危前列腺癌的AUC为0.829、灵敏度90.4%、特异度65.3%。

要点

  • 高危前列腺癌原发灶SUVmax显著高于中危(中位16.85 vs 7.80,P<0.001)。
  • SUVmax与PSA水平(r=0.561)及Gleason评分(r=0.496)呈正相关(P<0.001)。
  • SUVmax界值9.05识别高危前列腺癌:AUC 0.829,灵敏度90.4%,特异度65.3%。

核心结论

  • 18F-PSMA-1007 PET/CT对高危前列腺癌显示出较强的诊断效能,可作为临床参考的客观影像学指标。

研究设计与样本

  • 回顾性分析101例原发性非转移性前列腺癌患者,均行18F-PSMA-1007 PET/CT。
  • 依据欧洲泌尿外科学会前列腺癌指南将患者分为中危组(49例)和高危组(52例)。
  • 测量原发前列腺肿瘤SUVmax,计算PET/CT对中危和高危前列腺癌的诊断效能,并分析SUVmax与PSA水平及Gleason评分的关系。

主要发现

  • PSA水平与SUVmax呈显著正相关(r=0.561,P<0.001)。
  • Gleason评分与SUVmax呈显著正相关(r=0.496,P<0.001)。
  • Gleason评分6和7a的肿瘤18F-PSMA-1007摄取显著低于Gleason评分8和9(P<0.01)。
  • 高危组SUVmax显著高于中危组(中位SUVmax:16.85 vs 7.80;P<0.001)。

关键数值与推荐

  • 受试者工作特征曲线分析中,识别高危前列腺癌的SUVmax最佳界值为9.05。
  • 该界值对应曲线下面积0.829,灵敏度90.4%,特异度65.3%。

临床怎么用

  • 18F-PSMA-1007 PET/CT原发灶SUVmax可作为高危前列腺癌风险分层的客观影像参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical management decisions on prostate cancer (PCa) are often based on a determination of risk. 68Ga-prostate-specific membrane antigen (PSMA)-11-positron emission tomography (PET)/computer tomography (CT) is an attractive modality to assess biochemical recurrence of PCa, detect metastatic disease and stage of primary PCa, making it a promising strategy for risk stratification. However, due to some limitation of 68Ga-PSMA-11 the development of alternative tracers is of high interest. In this study, we aimed to investigate the value of 18F-PSMA-1007 in identifying non-metastatic high-risk PCa. METHODS: A total of 101 patients with primary non-metastatic PCa who underwent 18F-PSMA-1007 PET/CT were retrospectively analyzed. According to the European Association of Urology guidelines on PCa, patients were classified into intermediate-risk (IR) group or high-risk (HR) group. The maximum standardized uptake values (SUVmax) of the primary prostate tumor were measured on PET/CT images. The diagnostic performance of PET/CT for IR and HR PCa was calculated, and the relationship between the SUVmax of primary prostate tumor, prostate-specific antigen (PSA) level and Gleason score (GS) was analyzed. RESULTS: Of all 101 patients, 49 patients were classified into IR group and 52 patients were classified into HR group. There was a significant positive correlation between PSA level/GS and SUVmax (r = 0.561, r = 0.496, P < 0.001, respectively). Tumors with GS 6 and 7a showed significantly lower 18F-PSMA-1007 uptake compared to patients with GS 8 and 9 (P < 0.01). SUVmax in patients of HR was significantly higher than those of IR (median SUVmax: 16.85 vs 7.80; P < 0.001). In receiver operating characteristic curve analysis, the optimal cutoff value of the SUVmax for identifying high-risk PCa was set as 9.05 (area under the curve: 0.829; sensitivity: 90.4%; specificity: 65.3%). CONCLUSION: 18F-PSMA-1007 PET/CT showed the powerful diagnosis efficacy for high-risk PCa, which can be used as an objective imaging reference index for clinical reference.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Hong JJ, Liu BL, Wang ZQ, et al. The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer. EJNMMI Res. 2020. PMID: 33169183. doi:10.1186/s13550-020-00730-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。